The combination of resveratrol and erlotinib could decrease the p-Akt, p-mTOR, and p-S6K relative to either agent alone, indicating the synergistic suppression of the Akt/mTOR pathway in NSCLC [32]. Here, RPS6KB1 is linked to non-small cell lung carcinoma.